Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-04T16:16:20.625Z Has data issue: false hasContentIssue false
  • English
  • Français

Parkinson's disease exacerbated by paroxetine

Published online by Cambridge University Press:  13 June 2014

Laura Mannion ,
Sheila O'Sullivan ,
PA Carney  and
John Moran
John Moran
Affiliation:
University College Hospital Galway, Co Galway, Ireland
Get access Rights & Permissions [Opens in a new window]

Abstract

Patients with Parkinson's disease are frequently treated by psychiatrists. We report on the exacerbation of parkinsonian symptoms in tw o patients prescribed paroxetine, an SSRI antidepressant. We discuss the possible mechanism for such an interaction.

Keywords

Parkinson's diseaseParoxetineBasal ganglia diseases
Type
Case Reports
Information
Irish Journal of Psychological Medicine , Volume 14 , Issue 2 , June 1997 , pp. 74 - 75
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Jansen Steur, ENH. Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43: 211–3.CrossRefGoogle Scholar
2.Meltzer, HY, Young, Met al.Extrapyramidal side-effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979; 45: 165–75.CrossRefGoogle ScholarPubMed
3.Tate, JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989; 146(3): 399–400.Google Scholar
4.Bouchard, RH, Pourcher, E, Vincent, P. Fluoxetine and extrapyramidal sideeffects. Am J Psychiatry 1989; 146(10): 1352–3.Google Scholar
5.TM, Brod. Fluoxetine and extrapyramidal side-effects. Am J Psychiatry 1989; 146(10): 1353.Google Scholar
6.Baldwin, D, Fineberg, N, Montgomery, D. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991; 6: 51–8.CrossRefGoogle ScholarPubMed
7.Wils, V. Extrapyramidal symptoms in a patient treated with fluvoxamine. J Neurol Neurosurg Psychiatry 1992; 55: 330–1.CrossRefGoogle Scholar
8.Committee on Safety of Medicines. Dystonia and withdrawal symptoms with paroxetine. Curr Probl Pharmacol 1993; 19: 1.Google Scholar
9.Paroxetine and dystonia. Pharmaceut J 1993; 250: 303.Google Scholar
10.Nicholson, SD. Extrapyramidal side effects associated with paroxetine. West Engl Med J 1992; 107(3): 90–1.Google ScholarPubMed
11.Jimenez-Jimenez, FJ, Tejeiro, Jet al.Parkinsonism exacerbated by paroxetine. Neurology 1994; 44: 2406.CrossRefGoogle ScholarPubMed
12.Chase, TN. LKY, Ng, Watanabe, AM. Parkinson's disease. Modification by 5-hydroxytryptophan. Neurology 1972; 22: 479–84.CrossRefGoogle ScholarPubMed
13.Hall, CD, Weiss, EAet al.Rapid deterioration in patients with parkinsonism following tryptophan-pyridoxine administration. Neurology 1972; 22: 231–7.CrossRefGoogle ScholarPubMed
14.Baldessarini, RJ, Marsh, E. Fluoxetine and side-effects. Arch Gen Psychiatry 1990; 47: 191–2.CrossRefGoogle ScholarPubMed
15.Cummings, JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 4: 443–54.Google Scholar